Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.69 |
| ▸ | GABRD | O14764 | 3/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.69 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.69 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.69 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.69 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.69 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.69 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.69 |
| ▸ | GABRE | P78334 | 3/20 | 0.69 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.69 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.69 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.69 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24100560 | 0.85 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8072226 | 0.85 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1969600 | 0.83 | GABRP (0.72) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2859498 | 0.81 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25571855 | 0.81 | TUBB4A (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31172721 | 0.81 | TUBB4A (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9630374 | 0.80 | TSHR (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10513365 | 0.79 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2518980 | 0.79 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28896088 | 0.78 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | claimed |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-05-18 | — | — | US | claimed |
| WO-2005123713-A1 | PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-12-29 | — | — | WO | claimed |
| EP-3492451-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3288942-B1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-10-27 | — | — | EP | disclosed |
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-10 | — | — | US | disclosed |
| CN-107531715-B | RSV antiviral pyrazolo-and triazolo-pyrimidine compounds | 爱尔兰詹森科学公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-07-16 | — | — | US | disclosed |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| US-10611769-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2020-04-07 | — | — | US | disclosed |
| WO-1992006092-A1 | ACETYLENES DISUBSTITUTED WITH A HETEROAROMATIC GROUP AND A 2-SUBSTITUTED CHROMANYL, THIOCHROMANYL OR 1,2,3,4-TETRAHYDROQUINOLINYL GROUP HAVING RETINOID-LIKE ACTIVITY | ALLERGAN, INC. (US) | 1992-04-16 | — | — | WO | disclosed |
| US-5089509-A | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC. (US) | 1992-02-18 | — | — | US | disclosed |
| US-5053523-A | Chemical intermediate for compounds having retinoic acid-like activity | ALLERGAN, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-5045551-A | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0436398-A1 | Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity | ALLERGAN, INC. (US) | 1991-07-10 | — | — | EP | disclosed |
| US-5023341-A | Acetylene thiochroman | ALLERGAN, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| US-5013744-A | Skin disorders | ALLERGAN, INC. (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0419132-A2 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0419130-A2 | Acetylenes disubstituted with a heteroaromatic group and A 2-substituted chromanyl, thiochromanyl or 1,2,3,4- tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | GABRP 352/4885GABRD 875/4885GABRA1 912/4885 |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | GABRP 2713/4885GABRD 4130/4885GABRA1 3478/4885 |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | GABRP 2713/4885GABRD 4130/4885GABRA1 3478/4885 |
| US-10611769-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | GABRP 2713/4885GABRD 4130/4885GABRA1 3478/4885 |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | CBR3, NR1H2, NR3C2 | GABRP 2287/4885GABRD 2616/4885GABRA1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.